Skip to main content

Drug Interactions between darifenacin and vibegron

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

darifenacin vibegron

Applies to: darifenacin and vibegron

MONITOR: Concomitant use of vibegron with antimuscarinic agents used in the treatment of overactive bladder (OAB) may increase the risk of urinary retention. Urinary retention has been reported in clinical trials and in the postmarketing period with use of vibegron.

MANAGEMENT: Caution is advised if vibegron is prescribed in combination with antimuscarinic medications used for the treatment of OAB. Vibegron should be discontinued in patients who develop urinary retention.

References (1)
  1. (2021) "Product Information. Gemtesa (vibegron)." Urovant Sciences, Inc

Drug and food/lifestyle interactions

Minor

darifenacin food/lifestyle

Applies to: darifenacin

The consumption of grapefruit juice may be associated with increased plasma concentrations of darifenacin. The mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. The clinical significance is unknown.

References (1)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer